[Form 4] Zomedica Corp. Insider Trading Activity

Rhea-AI Filing Summary

Kevin Klass, Senior Vice President, Sales at Zomedica Corp., reported purchases of 60,723 shares on 08/11/2025 at $0.04, and 250,000 and 745,341 shares on 08/12/2025 at $0.04. Following these reported transactions, his beneficial ownership is shown sequentially as 4,260,753, 4,510,753 and 5,256,094 shares.

Positive

• Multiple insider purchases disclosed with transaction details and post-transaction ownership figures reported
• All purchases executed at $0.04, with explicit per-transaction amounts and resulting beneficial ownership shown
• Derivative table is empty, indicating no new derivative positions reported in this filing

Negative

• None.

Insights

Financial Analyst

TL;DR: Kevin Klass purchased company shares at $0.04, increasing reported ownership to 5,256,094 shares.

The Form 4 discloses three purchase transactions by Kevin Klass: a purchase of 60,723 shares on 08/11/2025 and purchases of 250,000 and 745,341 shares on 08/12/2025, each at $0.04. The entries list resulting beneficial ownership levels after each trade. No dispositions or derivative transactions are reported in the filing.

Corporate Governance Expert

TL;DR: Insider purchases are documented and transparent; Form 4 shows only purchases with increasing direct beneficial ownership.

The filing identifies Kevin Klass as an officer and reports only non-derivative purchases coded as purchases. Table II for derivative securities is empty, and the form provides the post-transaction beneficial ownership figures of 4,260,753, 4,510,753 and 5,256,094 shares. The disclosure is orderly and conforms to Form 4 reporting structure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klass Russell Kevin

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE, STE 100

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr Vice President, Sales

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, without par value	08/11/2025		P		60,723	A	$0.04	4,260,753	D
Common Stock, without par value	08/12/2025		P		250,000	A	$0.04	4,510,753	D
Common Stock, without par value	08/12/2025		P		745,341	A	$0.04	5,256,094	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kevin Klass	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ZOM report on this Form 4?

Kevin Klass reported three purchases: 60,723 shares on 08/11/2025 at $0.04, and 250,000 and 745,341 shares on 08/12/2025 at $0.04.

How did Kevin Klass's beneficial ownership change after the reported trades?

The filing shows sequential reported beneficial ownership of 4,260,753, then 4,510,753, and finally 5,256,094 shares following the transactions.

What price were the Zomedica (ZOM) shares purchased at in these transactions?

Each reported purchase was executed at $0.04 per share.

Were any derivative securities reported in this Form 4 for ZOM?

No. Table II for derivative securities is empty in the provided filing.

What is Kevin Klass's role at Zomedica as listed on the Form 4?

He is identified as Senior Vice President, Sales and is a reporting person on the Form 4.